title: Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study.
abstract: BACKGROUND
  Studies have showed that 10-day sequential treatment regimen achieved higher Helicobacter pylori eradication rate than standard triple therapies.
  
  
  OBJECTIVE
  To compare a 10-day sequential therapy and standard triple therapy in Chinese children with H. pylori infection.
  
  
  METHODS
  A prospective, multicentre, open-label, randomised controlled trial was conducted in four tertiary medical centres in China. Children with H. pylori gastritis were randomly assigned to a 10-day sequential therapy consisting of omeprazole and amoxicillin for 5 days followed by omeprazole, clarithromycin and metronidazole for the remaining 5 days, or 7-day or 10-day standard triple therapy comprising of omeprazole, amoxicillin and clarithromycin. H. pylori eradication was assessed by H. pylori stool antigen test.
  
  
  RESULTS
  A total of 360 patients were included. The eradication rate achieved with the 10-day sequential therapy was significantly higher than either the 7-day or 10-day standard triple treatment, either by the intention-to-treat analysis (81.4% vs. 61.9% or 67.7%, P < 0.05) or per-protocol analysis (89.7% vs. 70.8% or 77.8%, P < 0.05).
  
  
  CONCLUSIONS
  The 10-day sequential regimen was significantly more effective than standard 7-day or 10-day triple regimens in eradicating H. pylori infection in Chinese children.
authors.affiliation: Guangzhou Women and Children's Medical Center of Guangzhou Medical College, Guangzhou, China.
authors.forename: J
authors.initials: J
authors.lastname: Huang
authors.forename: L
authors.initials: L
authors.lastname: Zhou
authors.forename: L
authors.initials: L
authors.lastname: Geng
authors.forename: M
authors.initials: M
authors.lastname: Yang
authors.forename: X-W
authors.initials: XW
authors.lastname: Xu
authors.forename: Z-L
authors.initials: ZL
authors.lastname: Ding
authors.forename: M
authors.initials: M
authors.lastname: Mao
authors.forename: Z-L
authors.initials: ZL
authors.lastname: Wang
authors.forename: Z-L
authors.initials: ZL
authors.lastname: Li
authors.forename: D-Y
authors.initials: DY
authors.lastname: Li
authors.forename: S-T
authors.initials: ST
authors.lastname: Gong
mesh_terms: D000293:Adolescent; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D044466:Asian People; D002648:Child; D002675:Child, Preschool; D002681:China; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D008795:Metronidazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole